香港联交所最新资料显示，8月8日，叶永春减持立高控股(08472)450万股，每股作价0.405港元，总金额 为182.25万港元。减持后最新持股数目为561.45万股，最新持股比例为4.87%。 ...

大唐西市(00620)发布公告，林晓凌已获委任为执行董事;及戴智杰已获委任为独立非执行董事，自2025 年8月8日起生效。 戴智杰已获委任为董事会审核委员会及薪酬委员会成员;及蔡宏图已获调任为薪酬委员会主席，自2025 年8月8日起生效。 ...

Group 1 - BlackRock invested over $1.2 billion in ETH, significantly outpacing its $267 million investment in BTC, indicating a shift in Wall Street's capital direction from Bitcoin as "digital gold" to Ethereum as "digital oil" [1] - The rapid growth of BlackRock's Ethereum ETF (ETHA) from $5 billion to over $10 billion in just 10 days reflects changing investor sentiment towards Ethereum [1] Group 2 - Huajian Medical announced its transformation into the first enhanced Ethereum treasury company in Hong Kong, marking a strategic advancement in the market [2] - The company initiated a global enhanced Ethereum treasury strategy with a multi-layered "downside protection" mechanism and active "yield enhancement" strategies [3] Group 3 - Huajian Medical partnered with HashKey Group to establish a compliant trading channel for large-scale ETH transactions and to explore the integration of crypto assets with real-world assets (RWA) [6] - The company approved the purchase of 5,190 ETH at an average price of HKD 28,798.21, totaling HKD 149 million, as a significant step in its treasury strategy [7] Group 4 - Wall Street's consensus indicates that Ethereum is becoming a necessary asset for institutional investment, supported by five core value pillars including its deflationary nature and yield generation capabilities [8][9] - Ethereum's role as a foundational settlement asset in the DeFi ecosystem positions it as a preferred choice for RWA tokenization and stablecoin issuance [9] Group 5 - Huajian Medical's Ethereum treasury strategy is closely linked to its core business of medical RWA tokenization, aiming to create a unique ecosystem for innovative drug assets [10] - The company's ivd.xyz exchange is designed to facilitate the issuance and trading of medical RWA, integrating Ethereum as a core asset for governance and liquidity [10] Group 6 - The treasury strategy includes an "insurance mechanism" to mitigate volatility risks and a systematic investment approach to smooth costs [13][14] - Huajian Medical aims to address the challenges in innovative drug development financing through its tokenization strategy, enhancing investment efficiency [15] Group 7 - The market is recognizing the potential for Huajian Medical's treasury model to achieve significant valuation, drawing parallels to MicroStrategy's success with Bitcoin [17] - The company's stock price surged by 118% in July and 38.43% on August 6, indicating strong market interest and potential for value discovery [19] Group 8 - Huajian Medical's strategic vision includes applying for stablecoin licenses in both Hong Kong and the U.S., aiming to connect innovative drug assets with global capital through the Ethereum ecosystem [24] - The company's ambition is to leverage Ethereum's properties to create a new benchmark in the Hong Kong market, facilitating the global circulation of Chinese biomedical assets [24]

董事会预期集团于该期间将由亏转盈，主要受惠于门店数量较去年同期增加，带动收入增长。此外，集 团积极优化营运流程及调整办公室人力架构，以提升运营效率并控制成本。这些因素共同促使经营溢利 较去年同期有所增长。 格隆汇8月8日丨味千(中国)(00538.HK)发布公告，与上年同期公司拥有人应占亏损约人民币7.2百万元相 比，预期截至2025年6月30日止六个月将扭亏为盈，录得公司拥有人应占溢利介于约人民币10.0百万元 至40.0百万元。 ...

格隆汇8月8日丨永利地产发展(00864.HK)发布公告，董事会会议将于2025年8月22日举行，藉以（其中 包括）考虑及批准公司及其附属公司截至2025年6月30日止六个月的中期业绩，并考虑是否要派发中期 股息。 ...

Group 1 - The company expects a significant reduction in loss for the first half of 2025, with an estimated loss not exceeding 33 million HKD, compared to a loss of 79.917 million HKD in the same period of 2024, representing a decrease of approximately 59% [1] - The improvement in operational performance is primarily attributed to successful cost control measures, which have led to an increase in gross margin and a reduction in administrative expenses [1] - The company also received compensation income of approximately 14 million HKD from insurance claims related to damages caused by heavy rainfall to construction sites in Hainan during 2024 [1]

毛利率改善—毛利率由去年同期的1.51%上升至本期间的3.64%。有此改善，乃主要由于集团结束无盈 利或低利润的业务，并在客户及产品组合方面实施策略性调整，将重心转向高附加价值产品。同时，集 团持续优化产能利用率、提升效率、优先将资金用于支援未来业务发展，同时着力严格管控开支及削减 成本。我们亦于重组业务、精简间接人员及厂区整合方面取得进展，特别是应对中国业务持续收缩的情 况。 三大业务发展—于智能制造领域，集团积极优化客户组合，配合策略目标审慎拓展客户。在车载电子方 面，集团的4G车载通信控制单元(TCU)达成重要里程碑，向一家全球汽车制造商出货超过一百万套，并 获多个国际汽车品牌应用。在生产线设备╱机器人业务方面，集团的智能回收机器人持续获北美市场青 睐。此外，集团与客户紧密合作，从零开始共同开发全自动化生产线，有效应对劳工短缺的问题，进一 步提升营运效率。 智通财经APP讯，富智康集团(02038)发布截至2025年6月30日止6个月中期业绩公告，该集团取得营业收 入20.61亿美元，同比增加8.75%;公司拥有人期间溢利616.5万美元，去年同期亏损3157.8万美元;每股基 本盈利0.8美仙。 公告 ...

智通财经APP讯，贝壳-W(02423)发布公告，于2025年8月7日该公司斥资约500万美元回购84.5万股，回 购价格为每股5.85-6.00美元。 ...

智通财经APP获悉，香港联交所最新资料显示，8月8日，叶永春减持立高控股(08472)450万股，每股作 价0.405港元，总金额为182.25万港元。减持后最新持股数目为561.45万股，最新持股比例为4.87%。 ...

格隆汇8月8日丨贝壳-W(02423.HK)发布公告，2025年8月7日耗资500万美元回购84.5万股。 ...